((自动化翻译由路透提供，请见免责声明 ))
12月10日 - ** 药物开发商CervoMed 股价盘前下跌71.3%至2.90美元
** 该公司称其药物neflamapimod在一项治疗路易体痴呆症的中期试验中没有达到 (link) 主要和次要目标$(DLB)$
** 路易体痴呆症是一种痴呆症，是由于大脑神经细胞中被称为路易体的蛋白质沉积物堆积所致。
** CRVO称，药物neflamapimod没有达到试验的主要目标，即显著减轻痴呆症症状。
** CervoMed公司首席执行官约翰-阿拉姆（John Alam）表示，公司将暂停此前计划的该疗法后期试验的所有准备工作，直到试验数据的全面分析完成为止。
** 截至上日收盘，股价累计上涨 34.3
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.